A detailed history of Allspring Global Investments Holdings, LLC transactions in Arvinas, Inc. stock. As of the latest transaction made, Allspring Global Investments Holdings, LLC holds 7,371 shares of ARVN stock, worth $140,638. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,371
Previous 14,298 48.45%
Holding current value
$140,638
Previous $380,000 52.37%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$23.66 - $32.73 $163,892 - $226,720
-6,927 Reduced 48.45%
7,371 $181,000
Q2 2024

Jul 26, 2024

BUY
$24.46 - $40.4 $42,266 - $69,811
1,728 Added 13.75%
14,298 $380,000
Q1 2024

Apr 18, 2024

BUY
$36.38 - $52.31 $38,562 - $55,448
1,060 Added 9.21%
12,570 $518,000
Q4 2023

Jan 25, 2024

BUY
$14.19 - $42.33 $46,458 - $138,588
3,274 Added 39.75%
11,510 $473,000
Q3 2023

Oct 27, 2023

BUY
$19.64 - $28.21 $161,755 - $232,337
8,236 New
8,236 $161,000
Q2 2023

Jul 18, 2023

BUY
$21.73 - $31.43 $45,437 - $65,720
2,091 Added 6.06%
36,579 $907,000
Q1 2023

Apr 13, 2023

BUY
$26.15 - $37.26 $5,151 - $7,340
197 Added 0.57%
34,488 $942,000
Q4 2022

Jan 23, 2023

BUY
$32.47 - $57.24 $16,884 - $29,764
520 Added 1.54%
34,291 $0
Q3 2022

Oct 26, 2022

SELL
$41.87 - $57.99 $33,328 - $46,160
-796 Reduced 2.3%
33,771 $1.5 Million
Q2 2022

Jul 25, 2022

SELL
$36.01 - $74.24 $279,905 - $577,067
-7,773 Reduced 18.36%
34,567 $1.45 Million
Q1 2022

May 02, 2022

BUY
$60.27 - $81.57 $226,133 - $306,050
3,752 Added 9.72%
42,340 $2.85 Million
Q4 2021

Jan 28, 2022

BUY
$65.85 - $96.21 $2.54 Million - $3.71 Million
38,588 New
38,588 $3.17 Million

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.02B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Allspring Global Investments Holdings, LLC Portfolio

Follow Allspring Global Investments Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allspring Global Investments Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Allspring Global Investments Holdings, LLC with notifications on news.